Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria S Tretiakova

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Scientific Reports|January 4, 2024
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarkerShiqin Liu, Sarah J Hawley, Christian A Kunder, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 13, 2024
Molecular Characterization of Juxtaglomerular Cell Tumors: Evidence of Alterations in MAPK-RAS PathwayJoão Lobo, Sofia Canete-Portillo, Maria Del Carmen Rodriguez Pena, et al.
JAMA|May 30, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate CancerLisa F Newcomb, Jeannette M Schenk, Yingye Zheng, et al.
Histopathology|June 3, 2024
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stageJane K Nguyen, Lara R Harik, Eric A Klein, et al.
The American Journal of Surgical Pathology|September 17, 2016
Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective CohortJesse K McKenney, Wei Wei, Sarah Hawley, et al.
International Journal of Surgical Pathology|October 17, 2022
Characterization of Intercalated Cell Markers KIT and <i>LINC01187</i> in Chromophobe Renal Cell Carcinoma and Other Renal NeoplasmsRahul Mannan, Xiaoming Wang, Pushpinder S Bawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Neoadjuvant Enzalutamide Prior to ProstatectomyBruce Montgomery, Maria S Tretiakova, Anthony M Joshua, et al.
Clinical Genitourinary Cancer|November 8, 2020
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) ProgramLeonidas N Diamantopoulos, Sarah K Holt, Ali R Khaki, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 11, 2022
Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinomaEmily Chan, Jesse K McKenney, Sarah Hawley, et al.
Urologic Oncology|February 8, 2021
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomyLeonidas N Diamantopoulos, Rishi R Sekar, Sarah K Holt, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Scientific Reports|January 4, 2024
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarkerShiqin Liu, Sarah J Hawley, Christian A Kunder, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 13, 2024
Molecular Characterization of Juxtaglomerular Cell Tumors: Evidence of Alterations in MAPK-RAS PathwayJoão Lobo, Sofia Canete-Portillo, Maria Del Carmen Rodriguez Pena, et al.
JAMA|May 30, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate CancerLisa F Newcomb, Jeannette M Schenk, Yingye Zheng, et al.
Histopathology|June 3, 2024
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stageJane K Nguyen, Lara R Harik, Eric A Klein, et al.
The American Journal of Surgical Pathology|September 17, 2016
Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective CohortJesse K McKenney, Wei Wei, Sarah Hawley, et al.
International Journal of Surgical Pathology|October 17, 2022
Characterization of Intercalated Cell Markers KIT and <i>LINC01187</i> in Chromophobe Renal Cell Carcinoma and Other Renal NeoplasmsRahul Mannan, Xiaoming Wang, Pushpinder S Bawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Neoadjuvant Enzalutamide Prior to ProstatectomyBruce Montgomery, Maria S Tretiakova, Anthony M Joshua, et al.
Clinical Genitourinary Cancer|November 8, 2020
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) ProgramLeonidas N Diamantopoulos, Sarah K Holt, Ali R Khaki, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 11, 2022
Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinomaEmily Chan, Jesse K McKenney, Sarah Hawley, et al.
Urologic Oncology|February 8, 2021
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomyLeonidas N Diamantopoulos, Rishi R Sekar, Sarah K Holt, et al.
Pageof 9